000163951 001__ 163951
000163951 005__ 20230915090539.0
000163951 0247_ $$2doi$$a10.1055/a-1743-2915
000163951 0247_ $$2pmid$$apmid:35405744
000163951 0247_ $$2ISSN$$a0015-8194
000163951 0247_ $$2ISSN$$a0720-4299
000163951 0247_ $$2ISSN$$a1439-3522
000163951 037__ $$aDZNE-2022-00625
000163951 041__ $$aGerman
000163951 082__ $$a150
000163951 1001_ $$0P:(DE-2719)9001249$$aWagemann, Olivia$$b0$$eFirst author$$udzne
000163951 245__ $$aRegression bei jungen Erwachsenen mit einem Down-Syndrom: Eine Fallserie.
000163951 260__ $$aStuttgart [u.a.]$$bThieme$$c2022
000163951 3367_ $$2DRIVER$$aarticle
000163951 3367_ $$2DataCite$$aOutput Types/Journal article
000163951 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667897665_7091
000163951 3367_ $$2BibTeX$$aARTICLE
000163951 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163951 3367_ $$00$$2EndNote$$aJournal Article
000163951 520__ $$aRegression in young adults with Down syndrome can present itself with an acute loss of acquired skills and change in behavior. The aim of our case series was to describe the heterogeneous clinical presentation of this syndrome as well as accompanying diagnostic and therapeutic challenges and consequences.All three patients were assessed with the CAMDEX-DS (Cambridge Examination for Mental Disorders of Older People with Down Syndrome and Others with Intellectual Disabilities) and the criteria published by the DSMIG-USA (Down-Syndrome Medical Interest Group USA).After ruling out somatic or other psychiatric causes, the application of the DSMIG-USA criteria resulted in diagnosing at least a probable unexplained regression in all three patients.The thorough diagnostic investigation of unexplained acute regression in young adults with Down syndrome allows for quick initiation of therapeutic and supportive measures. Using the DMSIG-USA criteria facilitates the assessment of the underlying diffuse and heterogenous pathology.
000163951 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163951 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163951 650_2 $$2MeSH$$aAged
000163951 650_2 $$2MeSH$$aCognition
000163951 650_2 $$2MeSH$$aDown Syndrome: complications
000163951 650_2 $$2MeSH$$aHumans
000163951 650_2 $$2MeSH$$aIntellectual Disability: complications
000163951 650_2 $$2MeSH$$aYoung Adult
000163951 7001_ $$aLoosli, Sandra V$$b1
000163951 7001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b2$$udzne
000163951 7001_ $$0P:(DE-2719)9001508$$aPrix, Catharina$$b3$$udzne
000163951 7001_ $$aWlasich, Elisabeth$$b4
000163951 7001_ $$0P:(DE-2719)9001761$$aNuebling, Georg Sebastian Otto$$b5$$udzne
000163951 7001_ $$0P:(DE-2719)2810712$$aDanek, Adrian$$b6$$udzne
000163951 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b7$$eLast author$$udzne
000163951 773__ $$0PERI:(DE-600)2037701-0$$a10.1055/a-1743-2915$$gp. a-1743-2915$$n10$$p465-470$$tFortschritte der Neurologie, Psychiatrie$$v90$$x0015-8194$$y2022
000163951 909CO $$ooai:pub.dzne.de:163951$$pVDB
000163951 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001249$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000163951 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000163951 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001508$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000163951 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001761$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000163951 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810712$$aExternal Institute$$b6$$kExtern
000163951 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000163951 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163951 9141_ $$y2022
000163951 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000163951 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000163951 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000163951 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-26$$wger
000163951 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFORTSCHR NEUROL PSYC : 2021$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-26
000163951 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-26
000163951 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1$$lTranslational Neurodegeneration$$x0
000163951 9201_ $$0I:(DE-2719)1111015$$kAG Höglinger 2$$lCoordinator of Clinical Parkinson Research$$x1
000163951 9201_ $$0I:(DE-2719)1111016$$kClinical Dementia Research München$$lClinical Dementia Research München$$x2
000163951 980__ $$ajournal
000163951 980__ $$aVDB
000163951 980__ $$aI:(DE-2719)1110002
000163951 980__ $$aI:(DE-2719)1111015
000163951 980__ $$aI:(DE-2719)1111016
000163951 980__ $$aUNRESTRICTED